Unknown

Dataset Information

0

Response to angiotensin blockade with irbesartan in a patient with metastatic colorectal cancer.

ABSTRACT: BACKGROUND:A patient suffering from metastatic colorectal cancer, treatment-related toxicity and resistance to standard chemotherapy and radiation was assessed as part of a personalized oncogenomics initiative to derive potential alternative therapeutic strategies. PATIENTS AND METHODS:Whole-genome and transcriptome sequencing was used to interrogate a metastatic tumor refractory to standard treatments of a patient with mismatch repair-deficient metastatic colorectal cancer. RESULTS:Integrative genomic analysis indicated overexpression of the AP-1 transcriptional complex suggesting experimental therapeutic rationales, including blockade of the renin-angiotensin system. This led to the repurposing of the angiotensin II receptor antagonist, irbesartan, as an anticancer therapy, resulting in the patient experiencing a dramatic and durable response. CONCLUSIONS:This case highlights the utility of comprehensive integrative genomic profiling and bioinformatics analysis to provide hypothetical rationales for personalized treatment options.

SUBMITTER: Jones MR 

PROVIDER: S-EPMC4843189 | biostudies-literature | 2016 May

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

Response to angiotensin blockade with irbesartan in a patient with metastatic colorectal cancer.

Jones M R MR   Schrader K A KA   Shen Y Y   Pleasance E E   Ch'ng C C   Dar N N   Yip S S   Renouf D J DJ   Schein J E JE   Mungall A J AJ   Zhao Y Y   Moore R R   Ma Y Y   Sheffield B S BS   Ng T T   Jones S J M SJ   Marra M A MA   Laskin J J   Lim H J HJ  

Annals of oncology : official journal of the European Society for Medical Oncology 20160218 5

<h4>Background</h4>A patient suffering from metastatic colorectal cancer, treatment-related toxicity and resistance to standard chemotherapy and radiation was assessed as part of a personalized oncogenomics initiative to derive potential alternative therapeutic strategies.<h4>Patients and methods</h4>Whole-genome and transcriptome sequencing was used to interrogate a metastatic tumor refractory to standard treatments of a patient with mismatch repair-deficient metastatic colorectal cancer.<h4>Re  ...[more]

Similar Datasets

Unknown Synthetic Lethal Interaction with BCL-XL Blockade Deepens Response to Cetuximab in Patient-Derived Models of Metastatic Colorectal Cancer.
| S-EPMC10011886 | biostudies-literature
Unknown Immune Activation following Irbesartan Treatment in a Colorectal Cancer Patient: A Case Study.
| S-EPMC10051648 | biostudies-literature
Unknown Patient Blood Type Is Associated With Response to Immune Checkpoint Blockade in Metastatic Cancer.
| S-EPMC9438912 | biostudies-literature
Unknown Patient-derived organoids in cellulosic sponge model chemotherapy response of metastatic colorectal cancer.
| S-EPMC7803352 | biostudies-literature
Unknown Sustained complete response to CTLA-4 blockade in a patient with metastatic, castration-resistant prostate cancer.
| S-EPMC4418943 | biostudies-literature
Unknown Metastatic Colorectal Cancer Patient With Microsatellite Stability and BRAF<sup>V600E</sup> Mutation Showed a Complete Metabolic Response to PD-1 Blockade and Bevacizumab: A Case Report.
| S-EPMC8112237 | biostudies-literature
Unknown Prolonged Response to HER2-Directed Therapy in a Patient With HER2-Amplified, Rapidly Progressive Metastatic Colorectal Cancer.
| S-EPMC5564419 | biostudies-other
Unknown Antibiotic Exposure Does Not Impact Immune Checkpoint Blockade Response in MSI-H/dMMR Metastatic Colorectal Cancer: A Single-Center Experience.
| S-EPMC9632313 | biostudies-literature
Unknown Bevacizumab treatment in the elderly patient with metastatic colorectal cancer.
| S-EPMC4289484 | biostudies-literature
Unknown The genomic landscape of response to EGFR blockade in colorectal cancer.
| S-EPMC4878148 | biostudies-literature